News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
The role of TP53 and ctDNA kinetics in patients with R/R DLBCL
Photo of Carmelo Carlo-Stella from ematologyonair.com
Jul 16, 2024, 23:11

The role of TP53 and ctDNA kinetics in patients with R/R DLBCL

VJHemOnc (The Video Journal of Hematology and Hematological Oncology) shared a post on X:

”In an insightful recent interview, Carmelo Carlo-Stella (Humanitas University) speaks on the role of TP53 and ctDNA kinetics in patients with relapsed or refractory diffuse large B-cell lymphoma treated with glofitamab monotherapy. Watch here.”

Source: VJHemOnc/X

B-cell lymphoma cancer Carmelo Carlo-Stella glofitamab Humanitas University OncoDaily Oncology The Video Journal of Hematology and Hematological Oncology VJHemOnc
Special Coverage
Science
Feb 22, 2025, 16:16
Angela Lamarca: Current management of advanced HCC
Blog
Feb 22, 2025, 16:04
Eric Lehrer: Role of WBRT in multifocal LGG
Science
Feb 22, 2025, 16:00
Malak Alharbi: Diagnostic and therapeutic challenges in PRCA secondary to SMM
Blog
Feb 22, 2025, 15:54
Patrick Forde: Great day for lung cancer care
Science
Feb 22, 2025, 15:48
Shankar Siva: Whats new in stage IV cancer?
Science
Feb 22, 2025, 15:33
Updated ESMO Clinical Practice Guideline on Hepatocellular Carcinoma
Science
Feb 22, 2025, 15:14
Erman Akkus: Stage specific characterization of early-onset colorectal cancer
Blog
Feb 22, 2025, 15:04
John Gordon: Successful CAR Tcell Therapy - "It's a Bug's Life"
Blog
Feb 22, 2025, 14:43
Giannis Mountzios: How active ADCs against oncogene-addicted NSCLC?
Science
Feb 22, 2025, 14:10
Yan Leyfman: Advancing CAR T-Cell Therapy - Off-the-Shelf Allogeneic Approach
Science
Feb 22, 2025, 13:28
Elvina Almuradova: Immunotherapy for HPV-Associated Cancers
Opinion
Feb 22, 2025, 13:10
Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding